Execute pilot-scale bioreactor runs according to established protocols and procedures.
Prepare and manage bioreactor systems, media, and solutions.
Perform cell culture inoculation, monitoring, and sampling during bioreactor runs.
Monitor and control critical process parameters to ensure optimal cell growth and product expression.
Troubleshoot process deviations and implement corrective actions as needed.
Collaborate with cross-functional teams to analyze and interpret process data.
Document experimental procedures, results, and observations in electronic laboratory notebooks and reports.
Work with cross-functional teams to coordinate sample testing.
Maintain a clean and organized laboratory environment and adhere to safety guidelines and regulations.
About You:
Bachelor’s or advanced degree in chemical/biochemical engineering or related fields.
3-5 years of experience in pharmaceutical or gene therapy manufacturing, including GMP-regulated operations.
Hands-on experience in upstream cell culture process development and optimization, preferably in gene therapy.
Proficiency in operating and troubleshooting pilot-scale bioreactor systems, with a strong understanding of bioprocess engineering principles and practices.
Experience working with insect cell lines (e.g., Sf9) and viral vector production is highly desirable.
Experience with statistical analysis software (e.g., JMP) and data visualization tools is a plus.
Excellent communication and teamwork skills, with the ability to collaborate effectively across functional teams.
Detail-oriented with strong problem-solving abilities and a proactive approach to challenges.
Familiarity with regulatory guidelines and requirements for biologics manufacturing is a plus.
Some overtime required, as needed.
About Us:
Adverum, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
At Adverum, Inclusion and Diversity are at our core. We believe in the power of being your authentic self. We strive to create the space which allows for everyone in our Adverum Community to not only feel safe but encouraged to speak, learn from each other, grow in their professions and be the very best versions of themselves no matter what their age, ethnic background, gender, origin, religion or sexual orientation.